Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 6Neoplasm Metastasis 4Breast Neoplasms 3Neoplasms 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Hormone Refractory Prostate Cancer 2Bone Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Fractures, Bone 1Castration-resistant Prostate Cancer 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1Bone Neoplasms 1Bone Metastases 1Bone Diseases 1

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1bafetinib 1Mycobacterium w vaccine 1Docetaxel 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hormone Refractory Prostate Cancer × radium Ra 223 dichloride × Clear all
NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Bayer

Phase 2 Completed
100 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡